The VGF-derived Peptide TLQP21 Impairs Purinergic Control of Chemotaxis and Phagocytosis in Mouse Microglia

Nirmeen Elmadany,^{1,2*} Felipe de Almeida Sassi,^{1*} Stefan Wendt,¹ Francesca Loggiacco,¹ Josien Visser,¹ Verena Haage,¹ Daniel Perez Hernandez,³ Philipp Mertins,³ Dolores Hambardzumyan,⁴ Susanne Wolf,¹ Helmut Kettenmann,^{1†} and Marcus Semtner^{1‡}

¹Cellular Neurosciences, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany, ²Department of Biology, Chemistry, and Pharmacy, Institute of Pharmacy, Freie Universität Berlin, 12169, Berlin, Germany, ³Proteomics Platform, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association and Berlin Institute of Health, 13125 Berlin, Germany, and ⁴Department of Oncological Sciences, The Tisch Cancer Institute and Department of Neurosurgery, Mount Sinai Icahn School of Medicine, New York, New York 10029

Microglial cells are considered as sensors of brain pathology by detecting any sign of brain lesions, infections, or dysfunction and can influence the onset and progression of neurological diseases. They are capable of sensing their neuronal environment via many different signaling molecules, such as neurotransmitters, neurohormones and neuropeptides. The neuropeptide VGF has been associated with many metabolic and neurological disorders. TLQP21 is a VGF-derived peptide and has been shown to signal via C3aR1 and C1qBP receptors. The effect of TLQP21 on microglial functions in health or disease is not known. Studying microglial cells in acute brain slices, we found that TLQP21 impaired metabotropic purinergic signaling. Specifically, it attenuated the ATP-induced activation of a K^{+} conductance, the UDP-stimulated phagocytic activity, and the ATP-dependent laser lesion-induced process outgrowth. These impairments were reversed by blocking C1qBP, but not C3aR1 receptors. While microglia in brain slices from male mice lack C3aR1 receptors, both receptors are expressed in primary cultured microglia. In addition to the negative impact on purinergic signaling, we found stimulating effects of TLQP21 in cultured microglia, which were mediated by C3aR1 receptors: it directly evoked membrane currents, stimulated basal phagocytic activity, evoked intracellular Ca^{2+} transient elevations, and served as a chemotactic signal. We conclude that TLQP21 has differential effects on microglia depending on C3aR1 activation or C1qBP-dependent attenuation of purinergic signaling. Thus, TLQP21 can modulate the functional phenotype of microglia, which may have an impact on their function in health and disease.

Key words: C1qBP; C3aR1; microglia; purinergic signaling; TLQP21; VGF

Significance Statement

The neuropeptide VGF and its peptides have been associated with many metabolic and neurological disorders. TLQP21 is a VGF-derived peptide that activates C1qBP receptors, which are expressed by microglia. We show here, for the first time, that TLQP21 impairs P2Y-mediated purinergic signaling and related functions. These include modulation of phagocytic activity and responses to injury. As purinergic signaling is central for microglial actions in the brain, this TLQP21-mediated mechanism might regulate microglial activity in health and disease. We furthermore show that, in addition to C1qBP, functional C3aR1 responses contribute to TLQP21 action on microglia. However, C3aR1 responses were only present in primary cultures but not *in situ*, suggesting that the expression of these receptors might vary between different microglial activation states.

Introduction

Microglial cells are involved in essentially all brain diseases, including neurodegenerative disorders, traumatic brain injury, and

psychiatric diseases (Wolf et al., 2017). They constantly scan the environment and rapidly respond to brain injury (Davalos et al.,

Received June 21, 2019; revised Dec. 20, 2019; accepted Jan. 23, 2020.

Author contributions: N.E., F.d.A.S., S. Wendt, D.H., S. Wolf, H.K., and M.S. designed research; N.E., F.d.A.S., S. Wendt, F.L., J.V., V.H., P.M., D.P.H., and M.S. performed research; N.E., F.d.A.S., and M.S. contributed unpublished reagents/analytic tools; N.E., F.d.A.S., S. Wendt, and M.S. analyzed data; N.E., F.d.A.S., S. Wendt, D.H., H.K., and M.S. edited the paper; N.E. and M.S. wrote the paper.

This work was supported by Deutsche Forschungsgemeinschaft SFB TRR43, EXC 257 NeuroCure, Helmholtz-Gemeinschaft, Zukunftsthema Immunology and Inflammation ZT-0027, and Einstein-Stiftung. N.E. was supported by a Deutscher Akademischer Austauschdienst scholarship. We thank the Advanced Light Microscopy facility of the Max-Delbrück-Center Berlin-Buch for technical assistance with confocal microscopy and Imaris-based data analysis.

The authors declare no competing financial interests.

*N.E. and F.d.A.S. contributed equally to this work as first authors.

†H.K. and M.S. contributed equally to this work as last authors.

Correspondence should be addressed to Marcus Semtner at marcus.semtner@mdc-berlin.de.

S. Wendt's present address: Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada.

J. Visser's present address: Neuroglial Interactions in Cerebral Physiopathology, Center for Interdisciplinary Research in Biology, Collège de France, CNRS UMR 7241, INSERM U1050, Labex Memolife, PSL Research University, Paris, France.

S. Wolf's present address: Department of Ophthalmology, Charité, 13353 Berlin, Germany.

2005; Nimmerjahn et al., 2005). They are the professional phagocytes of the brain that remove dead cells and debris and therefore play an important role in brain homeostasis. Here we analyzed the role of a signaling peptide and its role in modulating microglial functions. VGF (nonacronymic) is a neuropeptide precursor that is widely expressed throughout the brain and is involved in many developmental and homeostatic processes, including neuronal differentiation, synaptic plasticity, and memory formation (Alder et al., 2003; Sato et al., 2012; Lin et al., 2015; Sakamoto et al., 2015). VGF is mainly expressed by neurons (Zhang et al., 2014) where it is hydrolyzed by prohormone convertase I and II enzymes into peptides before being secreted. VGF and its peptides are reported to be involved in many brain diseases, such as major depression disorder, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, and cancer (Lewis et al., 2015; Jiang et al., 2019; Llano et al., 2019; van Steenoven et al., 2019; Cocco et al., 2020). Several studies suggest VGF peptides as a potential biomarker, as CSF concentrations are often altered upon the onset and progression of brain diseases. Thus, in Alzheimer's disease (AD), VGF-derived peptides are significantly decreased in the CSF of AD patients (Carrette et al., 2003; Hendrickson et al., 2015; Spellman et al., 2015).

The C-terminal peptide of VGF, TLQP21, gained remarkable attention in the last years, being studied in contexts, such as neural cell survival (Severini et al., 2008), energy balance (Bartolomucci et al., 2006), lipolysis (Possenti et al., 2012), reproduction (Pinilla et al., 2011; Aguilar et al., 2013), blood pressure (Fargali et al., 2014), digestion (Severini et al., 2009), and pain (Rizzi et al., 2008; Chen et al., 2013; Fairbanks et al., 2014). Despite being studied in different neuroendocrine cell types, the role of TLQP21 in brain immunity exerted by microglia cells is still not known. Microglia express receptors, which are potentially activated by TLQP21, namely, C1qBP and C3aR1. TLQP21 has indeed been previously described as a ligand for these receptors indicating an involvement of this peptide in immunoregulation (Chen et al., 2013; Hannedouche et al., 2013). C3aR1 is a G-protein-coupled receptor expressed on cells of myeloid origin, including microglia, but also other cell types. VGF is involved in many biological processes, including neurogenesis and hormone release, insulin resistance, macrophage infiltration, and homing of hematopoietic progenitor cells to bone marrow (Klos et al., 2013). C1qBP is the first subcomponent of the classical pathway for complement activation, and it has been shown to bind to many different ligands involved in immune surveillance. The receptor is ubiquitously expressed and is present in various compartments of the cell. It also plays a role in different pathologies, including infection and carcinogenesis (Peerschke and Ghebrehiwet, 2007), which can be altered upon disease.

Here we studied the effects of TLQP21 on microglia and found that this VGF-derived peptide evoked intracellular Ca^{2+} elevations and outwardly rectifying membrane currents in microglia in a C3aR1-dependent fashion. Notably, we found that TLQP21 downregulates subsequent ATP and UDP-mediated purinergic membrane responses in a C1qBP-dependent manner. Many of the microglial features, such as phagocytic activity and directed process motility, are regulated by purinergic signaling (Haynes et al., 2006; Koizumi et al., 2007; Dissing-Olesen et al., 2014; Madry et al., 2018). Indeed, we found that, in acute brain slices, micro-

glial process movement toward a laser lesion and the stimulation of phagocytosis by UDP were decreased by preincubation of the slices with TLQP21, suggesting that the VGF-derived peptide TLQP21 impairs purinergic signaling and thereby microglial functions.

Materials and Methods

We investigated the effects of TLQP21 on microglia using either brain slices from C57BL/6J or MacGreen mice (*in situ*) or neonatal primary cultures from P1–P3 C57BL/6J mice (*in vitro*).

Animals. Experiments were performed using neonatal C57BL/6J male and female mice (Charles River Laboratories) for the primary cultures. For the *in situ* parts, 8- to 16-week-old C57BL/6J WT or MacGreen male mice (Sasmono and Williams, 2012) were used to allow for the detection of microglial cells by their fluorescence. Animals were kept according to the German law for animal protection under a 12 h/12 h dark-light cycle with food and water supply *ad libitum*.

Primary neonatal cultured microglia. For preparation of neonatal cultured microglia, P1–P3 male and female mice were used. After extraction of the brains, meninges and cerebellum were removed and put on ice with Hanks balanced salt solution (HBSS). The dissected brains were washed 3 times before adding trypsin (10 mg/ml, Biomol) and DNase (0.5 mg/ml, Worthington) in PBS. After 2–3 min of incubation, the reaction was blocked by adding DMEM containing 10% FCS. After removal of the medium, 0.2 mg DNase was added and the cells were mechanically dissociated. This step was repeated before centrifuging the cells 10 min at 800 rpm at 4°C. The supernatant was discarded. The pellet was resuspended in DMEM (cells from 2 brains/ml) and plated (cells from 2 brains/flask) in poly-L-lysine-coated flasks. After 24–48 h of incubation, the cultures were washed 3 times with PBS and allowed to grow until confluent in DMEM (5 d). After this incubation period, medium was replaced by DMEM with 33% L929 conditioned medium. After 2 d, cells were harvested by shaking them for 30 min at 100–110 rpm. The supernatant was centrifuged for 10 min at 800 rpm at 4°C. The cells were counted and plated onto coverslips (2.5×10^4 cells/coverslip). This procedure was repeated twice with 2 d intervals.

Whole-cell patch-clamp recordings. To test whether microglial cells display TLQP21 membrane current activity, we used the whole-cell patch-clamp technique on neonatal microglia *in vitro*. The pipette solution contained the following (in mM): 130 NaCl, 2 MgCl₂, 0.5 CaCl₂, 2 Na-ATP, 5 EGTA, 10 HEPES, and 0.01 sulforhodamine-101 (Sigma Millipore) with an osmolarity of 280–290 mOsm/L, adjusted to a pH of 7.3 with KOH. Patch pipettes were pulled from borosilicate glasses and had resistances of 4–6 Mohm. Cells were plated on coverslips with a density of 4 to 5×10^5 cells. For the *in situ* experiments, acute 250 μm coronal brain slices were prepared from male mice generated on a MacGreen background (Sasmono and Williams, 2012) for the identification of microglia by fluorescence on an epifluorescent microscope. The extracellular solution contained (in mM): NaCl, 134; KCl, 2.5; MgCl₂, 1.3; CaCl₂, 2; K₂HPO₄, 1.25; NaHCO₃, 26; D-glucose, 10; pH 7.4; 310–320 mOsm/L and was gassed with carbogen (95% O₂/5% CO₂). Conventional patch-clamp amplifiers were used (EPC9 or EPC10, HEKA). After establishing whole-cell configuration, we clamped the cell at a holding potential of -20 mV in voltage-clamp mode and applied a series of depolarizing and hyperpolarizing voltage steps ranging from -170 or -140 to 60 mV for 50 ms, each with 20 mV increments. This protocol was repeated every 5 s to continuously monitor membrane currents upon substance application. The recording chamber was perfused (4–6 ml/min) with standard recording buffer, which contained the following (in mM): 150 NaCl, 5.4 KCl, 2 CaCl₂, 1 MgCl₂, 10 HEPES, 10 glucose, adjusted with NaOH to pH 7.4. The peptide TLQP21 (1 nM, 10 or 100 nM) was applied via the bath perfusion for 1 min. The C3aR1 antagonist SB290157 (1 μM) (mAB-C1qBP) was applied 30 s before, during, and 30 s after peptide administration. For blocking C1qBP receptors, primary neonatal microglia and the MacGreen slices were incubated for 40–60 min with monoclonal anti-C1qBP antibodies (anti C1qBP mAB) in a concentration of 3 $\mu\text{g/ml}$ (Abcam). ATP was applied 3–5 min after TLQP21 application for 1 min.

Calcium imaging. For calcium imaging experiments, microglial cells were seeded on glass coverslips at a density of 2.5×10^4 cells per coverslip and allowed to adhere to the glass for 3 h. Cells were loaded with the calcium indicator Fluo4-AM (Thermo Fisher Scientific, F14201; 5 μ M in DMSO) dissolved in DMEM for 20–60 min at 37°C. The coverslip was then transferred to a recording chamber on an upright epifluorescence microscope equipped with a 20 $\times$ water-immersion objective (Olympus). There was a constant, local perfusion of buffer with a speed of 120 μ l/min through a Perfusion Pencil (AutoMate Scientific). The standard recording buffer contained the following (in mM): 150 NaCl, 5.4 KCl, 2 CaCl₂, 1 MgCl₂, 10 HEPES, 10 glucose, adjusted with NaOH to pH 7.4. Fluo4-AM was excited at 488 nm by a PolyChrome II or PolyChrome IV monochromator (Till Photonics), and pictures were taken at a frequency of 0.5 Hz by a Spot CCD camera (PCO). Exposure time was 100 ms. Images were acquired by CamWare version 3.16 software (PCO). Videos were analyzed using a home-made algorithm in Igor Pro 6.3 (WaveMetrics). For analysis, cell somata were selected as ROIs, and the mean relative fluorescent intensity for each ROI and frame was determined to record the change in Ca²⁺ levels time for each cell. Intracellular Ca²⁺ elevations were counted as “responsive” when the response amplitudes exceeded three times the SD of the baseline.

FACS of microglia. The 12- to 14-week-old male C57BL/6J mice were transcardially perfused under deep anesthesia with 1 $\times$ PBS. Brains were isolated, and after removal of the cerebellum and brainstem, dissociated into a single-cell suspension using Adult Brain Dissociation Kit (Miltenyi) and the gentleMACS dissociator (Miltenyi) according to the manufacturer's instructions. Subsequently, the cells were washed with PBS, passed through a 35 μ m nylon mesh, counted, and stained with anti-mouse CD11b⁺ PE-Cyanine7 (Invitrogen; Thermo Fisher Scientific) and anti-mouse CD45 eFluor 450 (Invitrogen; Thermo Fisher Scientific) for 20 min on ice. After staining, the cells were washed once in PBS and sorted with a FACS Aria flow cytometer (BD Biosciences) according to the specified gating strategy for microglia as CD11b⁺CD45^{low} cells, washed in PBS, and the cell pellets snap frozen for storage at -80°C .

Protein extraction and mass spectrometry analysis. Freshly isolated microglia populations from 4 different male C57BL/6J mice or 1×10^6 primary neonatal culture microglia per replicate were pooled and pelleted in PBS. The samples were solubilized in Laemmli buffer and subjected to SDS-PAGE. The proteome was processed as described previously (Shevchenko et al., 2006; Kanashova et al., 2015), using an automated HTS PAL system (CTC Analytics). Peptides were extracted, purified, and stored on reversed-phase (C18) StageTips (Rappsilber et al., 2007). The eluted peptides were lyophilized and resuspended in 0.1% formic acid/3% acetonitrile, then separated in a nano EasyLC 1200 (Thermo Fisher Scientific) with a 0.1 $\times$ 200 mm MonoCap C18 High Resolution Ultra column (GL Sciences) at a gradient from 5% to 95% B (80% acetonitrile, 0.1% formic acid) and a flow rate of 300 nL/min in 360 min. The UHPLC was coupled online to an Orbitrap Q Exactive plus mass spectrometer (Thermo Fisher Scientific) for mass spectrometry analysis. The mass spectrometer was set to acquire full-scan MS spectra (300–1700 m/z) at a resolution of 17,500 after accumulation to an automated gain control target value of 1×10^6 and maximum injection time of 20 ms, and was operated in a data-dependent acquisition mode, selecting the 10 most abundant ions for MS/MS analysis, with dynamic exclusion enabled (20 s). Charge state screening was enabled, and unassigned charge states and single charged precursors excluded. Ions were isolated using a quadrupole mass filter with a 1.2 m/z isolation window, with a maximum injection time of 60 ms. HCD fragmentation was performed at a normalized collision energy of 26. The recorded spectra were searched against a mouse database from Uniprot (January 2017) using the MaxQuant software package (version 1.5.2.8) (Cox and Mann, 2008) (with fixed modifications set to carbamylation of cysteines and variable modifications set to methionine oxidation). Peptide tolerance was 20 ppm, and the minimum ratio for LFQ was set to 2. The false discovery rate was set to 1% on protein and peptide level. Statistical analysis of the dataset was performed using R statistical software package (version 3.4.1), Prodigy (version 0.8.2), and Perseus software (version 1.6.0.7).

For data analysis, proteins that were only identified by site or were potential contaminants were excluded. Only those proteins discovered in

at least three biological replicates were used for column-wise analysis using a two-sample *t* test and a Benjamini-Hodgberg-based false discovery rate <0.05 .

Agarose spot assay. The agarose spot assay was performed as described previously (Wiggins and Rappoport, 2010). Low-melting point agarose (Promega) was diluted in sterile PBS to a 0.5% agarose solution, heated, and mixed to create PBS-, TLQP21 (1, 10, or 100 nM)-, or ATP (1 mM)-containing agarose spots (10 μ l). Two PBS control spots and two compound-containing spots were placed onto 35-mm-diameter glass-bottomed cell culture dishes (MatTek), and 0.5×10^6 WT microglia cells were added in either FCS-free DMEM medium as control or FCS-free DMEM medium containing 100 nM TLQP21, 1 μ M SB290157, or 1.5 μ g/ml C1qpPB mAB and incubated for 3 h at 37°C in 5% CO₂. Subsequently, microglial cells that invaded the spots were counted and normalized to the PBS control spots.

Scratch wound-healing assay. The scratch assay was performed as described previously with adaptations (Arbibe et al., 2000; Sarkar et al., 2004). Briefly, microglial cells were seeded at a density of 5×10^4 cells/dish in the glass-bottomed cell culture dish, and incubated at 37°C and 5% CO₂ for 24 h. A scratch wound was created with a 10 μ l pipette tip on the cell monolayer, and the cells were washed with PBS. Thereafter, the cells were stimulated with TLQP21-containing medium or PBS as a control for 3 h. Pictures were taken in premarked areas of the dish briefly after the scratch and 3 h thereafter. The pictures were analyzed using ImageJ, marking the initial cell-free zone and counting the cells that migrated into that area 3 h after treatment. The number of migrated cells was normalized to the average in control condition (100%). A minimum of three technical replicates from three individual cultures were used to calculate the mean migratory capacity of each cell culture condition.

Boyden chamber assay. TLQP21-induced chemotaxis was tested using a 48-well microchemotaxis Boyden chamber (Neuroprobe). Upper and lower wells were separated by a polycarbonate filter (8 μ m pore size; Poretics). Microglial cells ($2\text{--}5 \times 10^4$ cells) in 50 μ l of serum-free DMEM medium were added to the upper compartment, while the lower wells contained TLQP21-containing medium or medium only. Medium with the same concentration of the peptide in the lower well was added to the upper well with cells to assess motility in the absence of peptide gradient. Culture medium was used as a control. The chamber was incubated at 37°C and 5% CO₂ for 3 h. Cells remaining on the upper surface of the membrane were removed by wiping, and cells in the lower compartment were fixed in methanol for 5 min and subjected to Diff-Quik stain (Medion Grifols Diagnostics). The rate of microglial migration was calculated by counting cells in two fields of each well using a 10 $\times$ objective. The pictures were analyzed using ImageJ via the color threshold contrast tool (selecting colors in the hue range of 150 [upper] and 240 [lower], which are specific for the migrated cells stained in red-violet). The background area from the pores was subtracted for each experiment, followed by the calculation of the area for one cell (averaged from at least 10 representative migrated cells). For each condition, 40–120 fields in 10–30 wells were analyzed using cells from at least three independent microglia preparations. The number of cells in each field were normalized to the average in control condition (100%).

In vitro phagocytosis assay. We followed our standard protocol, which was previously described by Pannell et al. (2016). Yellow-green fluorescent Fluoresbrite carboxylated microspheres (3 μ m diameter, Polysciences) were coated with FCS by shaking at 1000 rpm for 30 min at room temperature. After centrifugation for 2 min at $900 \times g$, the supernatant was discarded and microspheres were washed and resuspended in HBSS; 4.8×10^6 microspheres in a solution containing either PBS only (control) or UDP (100 μ M) were applied on each coverslip with 5×10^4 seeded primary microglia for 30 min and incubated at 37°C. In another set of experiments, microglia were preincubated with 100 nM TLQP21 alone or in combination with SB290157 for 30 min before the phagocytosis assay; in these experiments, TLQP21 was washed out completely before the assay started. After washing with PBS, pH 7.4, the coverslips were fixed with 4% PFA, washed and blocked in TBS containing 5% donkey serum (EMD Millipore) and 0.1% Triton X (Carl Roth) for 1 h. Subsequently, the cells on the coverslips were stained with anti-Iba1 antibody (goat anti-Iba1, clone 5076, Abcam) in TBS containing 5%

Figure 1. TLQP21 impairs microglial signaling through purinergic P2RY receptors *in situ*. **A**, Transmission light and epifluorescent image of an acute brain slice from a male MacGreen mouse. Overview image represents the cortical region in which microglia were patch-clamped. A representative microglial cell is shown in higher resolution in the transmission light (Dodt gradient contrast) and in the epifluorescence (470 nm excitation) channel to show the EGFP labeling of the MacGreen mouse. **B**, Time course of a representative patch-clamp experiment on a microglial cell. Cells were voltage-clamped at -20 mV. A series of pulses ranging from -160 to 60 mV were applied every 5 s. TLQP21 (100 nM) was applied as indicated and led to no apparent changes in microglial membrane currents. **C**, Current–voltage relationships of the microglial recording shown in **B**. Time points are before (1) and during (2) the application of TLQP21, as indicated in **B**. There was no TLQP21-evoked change in membrane currents at any investigated membrane potential, as becoming visible by subtraction of the current–voltage relationships (2–1; green). **D**, **E**, Time courses of representative patch-clamp experiments on microglial cell. Either 10 μ M ATP (**D**) or 1000 μ M ATP (**E**) was applied without prior TLQP21 application (Control) or after a 1 min TLQP21 application (after TLQP21). All traces are from different recordings. Note the different appearance of the membrane responses upon 10 and 1000 μ M ATP, which occur due to the activation of microglial P2Y and P2X receptors, respectively. **F**, **G**, Average current density to voltage relationships (CD–V) of currents induced by 10 μ M (**F**) or 1000 μ M (**G**) ATP without (black) or with (green) prior TLQP21 application. **E**, CD–V relations are typical for metabotropic P2RY responses. **F**, CD–V relations resemble the characteristics of microglial P2X currents. After TLQP21 application, there was a significant decline in the amplitudes of P2RY responses, but not of P2RX responses. *** $p < 0.001$. n.s., Not significant ($p > 0.05$).

donkey serum overnight. After washing, the cells were incubated with the secondary antibody (anti-goat donkey AlexaFluor-647, Dianova) and DAPI (Sigma Millipore) before mounting with Aqua-Poly/Mount (Polysciences). Four or five images per coverslip were acquired from three coverslips per condition. Phagocytosed beads per cell were quantified with an in-house-written software and Igor Pro 6.3 (WaveMetrics). Cells were grouped to 1–4, 5–7, 8–10 beads per cell, and the percentage of cells in each group was multiplied by the corresponding grade of phagocytosis (1–4 beads: factor 1; 5–7 beads: factor 2; 8–10 beads: factor 3). The sum of the products in each group was then defined as the phagocytosis index.

In situ phagocytosis assay. Mice were killed by cervical dislocation. Brains were removed and cooled down in ice-cold ACSF containing the following (in mM): 134 NaCl, 2.5 KCl, 1.3 MgCl₂, 2 CaCl₂, 1.25 K₂HPO₄, 26 NaHCO₃, 10 D-glucose, pH 7.4 , gassed with 95% O₂/5% CO₂. Brains were mounted on a vibratome (HM650V, Thermo Fisher Scientific), and 130 - μ m-thick coronal slices were generated and incubated in ACSF for 2 h at room temperature, which was constantly gassed with carbogen (95% O₂/5% CO₂). Quantification of microglial phagocytic index in acute cortical brain slices of 130 μ m thickness was conducted in male C57BL/6J WT mice, based on a previously published protocol (Wendt et al., 2017). A total number of 6 mice as a control, 6 mice for TLQP21-treated slices, 3 mice for TLQP21 + SB290157-treated slices, and 3 mice for TLQP21 + mAB-C1qBP-treated slices were used; four slices per condition were obtained from each animal. We analyzed four randomly chosen FOVs per slice from cortical layers I–VI. Incubation with TLQP21

(100 nM), TLQP21 (100 nM) + SB290157 (1 μ M), or TLQP21 (100 nM) + mAB-C1qBP (3 μ g/ml) was done in the second hour within the first 2 h after slicing. After washout of the compounds, acute brain slices were incubated with a suspension of FCS-coated Bright Blue fluorescent carboxylated microspheres (4.5 μ m diameter, Polysciences). The fluorescent beads were opsonized with FCS by shaking at 1000 rpm for 30 min at room temperature followed by washing in PBS before adding them to the brain slices. Each brain section was incubated with 2.45×10^6 microspheres (in a volume of 500 μ l of HBSS) at 37°C for 1 h with or without 100 μ M UDP as indicated in Figure 7B. Last, sections were intensively washed with 0.1 M PBS (3×20 min) and subsequently fixed with 4% PFA for 1 h and washed with 0.1 M PBS. Sections were incubated in a permeabilization buffer containing 2% Triton X-100 (Carl Roth), 2% BSA (Carl Roth), and 10% normal donkey serum (EMD Millipore) in 0.1 M phosphate buffer, pH 7.4 , for 4 h, followed by the incubation with goat anti-Iba1 antibody ($1:600$; clone 5076 Abcam) in a dilution buffer ($1:10$ of permeabilization buffer in 0.1 M PBS, pH 7.4) at 4°C overnight. Thereafter, sections were incubated with the secondary antibody donkey anti-goat AlexaFluor-647 ($1:250$; Dianova) for 2 h at room temperature. After washing, slices were mounted in Aqua-Poly/Mount (Polysciences). Confocal laser scanning microscopy was performed on a TCS SPE using a $20\times$ oil-immersion objective (Leica Microsystems). We acquired 21 - μ m-thick z stacks at 1.05 μ m intervals beginning from the surface of the slice. Data analysis to assess microglial phagocytic activity was performed using Imaris 6.3.1 (Bitplane). The Iba1-positive volumes of high-resolution SPE confocal microscopy stacks were $3D$ surface rendered by application of threshold values of 40 and a “background subtraction” (90 μ m). Microspheres were detected as spots and counted automatically by the “Split into surface object” plugin. All beads

having their center located within a given rendered Iba1 volume were considered to be phagocytosed by microglia. The phagocytic index was calculated as follows: $n_{PM} \times 10^4 / V_{Iba1}$ where n_{PM} is the total number of phagocytosed microspheres and V_{Iba1} is the Imaris-rendered volume of Iba1 fluorescence in μm^3 .

Two-photon imaging and laser lesion. For two-photon imaging, 250 μ m coronal brain slices were obtained from MacGreen male mice. The total number of slices used was 18 , 12 , 10 , and 13 slices from 8 , 4 , 5 , and 5 mice for control, TLQP21-treated, TLQP21 + SB290157, and TLQP21 + mAB-C1qBP, respectively. EGFP was excited by a Chameleon Ultra II laser (Coherent) set to 940 nm. Images were acquired with a two-photon laser scanning microscope (Till Photonics) equipped with a water-immersion objective ($40\times$, NA 0.8 , Olympus). We imaged a 60 - μ m-thick z stack with a step size of 1 μ m covering a field of 320×320 μ m. Laser lesion was set in the cortex by focusing the laser beam, set to a wavelength of 810 nm and maximum power, at 20 μ m depth in the selected imaging volume, and scanned the tissue until autofluorescence of the injured tissue was visible. This procedure resulted in lesions with sizes ~ 20 μ m in the center of the observed region. To investigate the influence of TLQP21 on the microglial response to the laser lesion, we incubated the slices before the experiment for 60 min in ACSF containing TLQP21 (100 nM), TLQP21 (100 nM) + SB290157 (1 μ M), or TLQP21 (100 nM) + mAB-C1qBP (3 μ g/ml). Igor Pro 6.37 (WaveMetrics) was used for data analysis as in Davalos et al. (2005). Briefly, the sequences of

3D image stacks were converted into sequences of 2D images by a maximum intensity projection algorithm. For quantification, microglial response to the focal lesion was defined as a shift of EGFP fluorescence (white pixels), associated with microglial processes, from distal into the proximal circular region, immediately surrounding the focal lesion. To eliminate signal intensity differences between different records, grayscale images were first converted into a binary form using a threshold. Proximal, lesion region was defined as the midpoint of two circles with a diameter of 45 μm (x) and 240 μm (y). We calculated the pixels entering the inner circle ($R_x(t)$) in each frame over time subtracting the pixels of the first picture $R_x(0)$, thus highlighting movement of processes at the site of injury. This was then related to the pixels of the outer ring taken from the first picture directly after laser lesion ($R_y(0)$) to correct for the cell density around the lesion site. The microglial response is therefore given as $R(t) = [R_x(t) - R_x(0)]/R_y(0)$.

Quantification and statistical analysis. Statistical analysis was performed using Igor Pro 6.37 (WaveMetrics). For all comparisons of three or more groups, one-way ANOVA followed by a Tukey *post hoc* test was used. Comparisons between two samples were performed using the Student's *t* test. Column graphics display means, and error bars indicate the SEM.

Results

TLQP21 impairs microglial signaling through metabotropic purinergic receptors

To explore the effect of TLQP21 on microglia, we generated acute brain slices to record membrane currents in response to TLQP21 using the patch-clamp technique in the voltage-clamp configuration. We could identify microglia for patch-clamp experiments by using MacGreen male mice (Sasmono et al., 2003), which express EGFP in microglia (Fig. 1A). Consistent with previous data from us and other laboratories (for review, see Kettenmann et al., 2011), microglia displayed characteristic membrane currents when repetitively clamped at potentials between -170 and 60 mV (data not shown). The application of 100 nM TLQP21 did not evoke microglial membrane currents (Fig. 1B,C) in 24 recordings.

As in previous studies from our laboratory (Boucsein et al., 2000, 2003; Korvers et al., 2016; Wendt et al., 2017), we applied ATP at the end of our experiment as a control for cell viability (Fig. 1D,E). Under control conditions, the application of 10 μM ATP reliably evoked outwardly rectifying currents of 41.1 ± 10.8 pA at 60 mV that reversed close to the Nernst potential for K^+ (-83.9 ± 10.2 mV, $n = 10$; Fig. 1D,E), which were mediated by the activation of P2Y receptors triggering the activation of K^+ currents through THIK-1 (Butovsky et al., 2014; Ousingsawat et al., 2015; Madry et al., 2018). However, when TLQP21 was applied beforehand, the subsequent 10 μM ATP application did either induce no or only small currents compared with control

Figure 2. TLQP21 impairs microglial signaling through purinergic P2RY receptors in neonatal cultured microglia and evokes outwardly rectifying membrane currents. **A**, Representative patch-clamp experiments on neonatal cultured microglia. Top, Cells were voltage-clamped at -20 mV. A series of pulses ranging from -140 to 60 mV were applied every 5 s. TLQP21 at concentrations of 1 nM (left), 10 nM (middle), and 100 nM (right) was applied as indicated. Traces are all from the same recording. **B**, Average current density-voltage relationships of TLQP21-evoked currents, at 1 nM (light gray), 10 nM (gray), and 100 nM (green). $n = 7$ for each concentration. **C**, Summary of outward conductances (G_{outward}) determined between 20 and 60 mV evoked by TLQP21 at different concentrations. **D, E**, Time courses of representative patch-clamp experiments on microglia. Cells were voltage-clamped at -20 mV. Series of pulses ranging from -160 to 60 mV were applied every 5 s. Either 10 μM ATP (**D**) or 1000 μM ATP (**E**) was applied as indicated without prior TLQP21 application (Control) and 5 min after a 1 min TLQP21 application (After TLQP21). All traces are from different recordings. Note the different appearance of the membrane responses upon 10 and 1000 μM ATP, which occur due to the activation of microglial P2Y and P2X receptors, respectively. **F, G**, Average current density to voltage (CD-V) relationships of currents induced by 10 μM (**F**) or 1000 μM (**G**) ATP without (black) or with (green) prior TLQP21 application. **E**, CD-V relations are typical for metabotropic P2RY responses. **F**, CD-V relations resemble the characteristics of microglial P2X currents. After TLQP21 application, there was a significant decline in the amplitudes of P2RY responses, but not of P2RX responses. *** $p < 0.001$. n.s., Not significant ($p > 0.05$). See Figure 2-1.

recordings when TLQP21 was not applied, indicating that TLQP21 leads to an impairment of P2Y signaling. While at concentrations of 10 μM ATP only P2Y receptors are activated, at 1000 μM ATP also ionotropic P2X receptors are activated, in particular P2RX₇, the most common P2XR isoform in microglia, which conducts inwardly rectifying cationic currents. Thus, application of 1000 μM ATP activated a large membrane conductance, which reversed at 0 mV (Fig. 1G). We quantified currents in response to 1000 μM ATP 55 s after wash-in of ATP and found no differences between experiments with and without a previous application of TLQP21.

The impairment of microglial P2RY responses by TLQP21 in brain slices might be the result of TLQP21 action either directly

Figure 3. C3aR1 and C1qBP expression on microglia and their differential contribution to TLQP21 responses. **A**, Proteomic analysis of cultured and freshly isolated microglia demonstrates robust expression of C1qBP and reveals differential expression of C3aR1. Left, Scheme depicting the sample generation. To test microglial protein expression under *in situ* conditions, we freshly isolated microglia from adult male C57BL/6 mice by FACS. Microglia were first gated as CD11b⁺ cells against forward scatter and subsequently selected as CD45^{low} expressing cells (CD11b⁺ CD45^{low}). Protein from primary cultured microglia was directly isolated. Right, Protein expression of C1qBP and C3aR1 as iBAQ intensity of each protein. C1qBP was found in both microglia preparations, whereas there was no C3aR1 detected in freshly isolated microglia. **B**, **C**, TLQP21 current responses were recorded as shown in Figure 2A in primary cultured microglial cells. The C3aR1-specific inhibitor SB290157, but not C1qBP blockade by a monoclonal antibody (mAB-C1qBP), prevented microglial responses upon TLQP21, as demonstrated in the summarized current density to voltage (CD-V) relationships of TLQP21 responses (**B**) and the respective outward conductances (G_{outward}) determined between 20 and 60 mV (**C**). **D**, **E**, Current density to voltage (CD-V) relationships (**D**) and outward conductances (**E**) of microglial metabotropic ATP responses (10 μM) under control conditions (no TLQP21 application, control), after TLQP21 application and after TLQP21 application while blocking either C3aR1 or C1qBP. The decrease in metabotropic ATP responses depends on TLQP21 action on microglial C1qBP. *** $p < 0.001$. n.s., Not significant ($p > 0.05$).

on microglial cells or indirectly on nonmicroglial cells, such as neurons or astrocytes. To test for microglial TLQP21 receptors and thus provide evidence for a direct action of TLQP21 on microglial cells, we next investigated primary cultured microglial cells. We performed patch-clamp experiments and studied the TLQP21-evoked decreases in purinergic signaling (Fig. 2). In contrast to slices, application of 100 nM TLQP21 directly triggered outwardly rectifying currents (Fig. 2A,B), which reversed close to the Nernst potential for K^+ . The specific outward conductance of these currents between 20 and 60 mV was 57.8 ± 11.0 pS/pF (24 of 25 cells responding; Fig. 2C). Activation of these currents by TLQP21 was concentration-dependent, as it was lower at 10 nM TLQP21 (8.1 ± 3.6 pS/pF; 5 of 13 cells responding) and absent at 1 nM TLQP21 ($n = 11$). We tested the effect of low (10 μM) ATP concentrations to activate P2RY and high (1000 μM) ATP concentrations to activate P2RX responses in cultured microglia. Similar to the responses *in situ*, low ATP concentrations triggered a K^+ conductance, whereas high concentrations triggered a cationic conductance as shown in Figure 2D–F. TLQP21 treatment significantly reduced currents evoked by 10 μM ATP, indicating that the metabotropic (P2RY) component of microglial purinergic responses is considerably affected by

TLQP21. In some experiments, we observed that the inhibition of the K^+ conductance unmasks an underlying cationic conductance as shown in the example trace in Figure 2D. We also tested the impact of TLQP21 on P2X receptor currents (Fig. 2E,G). However, as *in situ*, there were no significant differences between P2XR currents under control conditions and after application of TLQP21 (Fig. 2G). In an attempt to further specify the identity of purinergic receptors activated at 10 μM ATP, we tested the specific P2RY₁₂ inhibitor AR-C69931 (Fig. 2-1). In the presence of 1 μM AR-C69931, outward currents upon 10 μM ATP between –170 and 60 mV were significantly reduced ($p = 0.0064$ to 0.0081 ; $n = 16$), indicating a major involvement of P2RY₁₂ in mediating responses upon 10 μM ATP. We conclude that TLQP21 evokes membrane currents in cultured microglia, but not *in situ* and that TLQP21 impairs P2Y, but not P2X purinergic responses both *in situ* and *in vitro*.

C1qBP and C3aR1 differentially contribute to TLQP21 actions on microglial cells

In previous studies, two different receptors for TLQP21 were identified, C3aR1 and C1qBP, both belonging to the complement receptor system (Chen et al., 2013; Hannedouche et al., 2013). We hypothesized that these two receptors could be responsible for the effects of TLQP21 on microglia purinergic signaling *in vitro* and *in situ*. We compared the protein expression levels of C3aR1 and C1qBP *in situ* and *in vitro* by proteomics. Data for *in situ* microglia (CD11b⁺ CD45^{low}) were obtained from microglial cells isolated by FACS from 12-week-old naive C57BL/6J male mice; *in vitro* data were obtained from neonatal cultured microglia. Protein expression levels of C3aR1 and C1qBP were calculated from the measured iBAQ intensities. As shown in Figure 3A, protein expression of C1qBP was equally high in cultured and freshly isolated microglia, whereas C3aR1 was detected in primary cultured microglia only. These data confirm a previously published proteomic screen (Sharma et al., 2015) and provide evidence for two different receptor systems that potentially mediate TLQP21 actions on microglia.

We next used the patch-clamp technique and used inhibitors for C3aR1 (SB290157) and C1qBP (an anti-C1qBP monoclonal antibody; mAB-C1qBP) to test whether or not these receptors are involved in the differential effects of TLQP21 on microglia. TLQP21-evoked currents were blocked by SB290157 inhibition (10 of 11 cells; Fig. 3B,C), indicating that these currents are activated downstream of C3aR1. Only in one cell, a small TLQP21 response was detected in the presence of the antagonist with an outward conductance of only 25% of the average TLQP21 response. To block C1qBP receptors, cultured microglia were incubated in mAB-C1qBP-containing medium (3 $\mu\text{g}/\text{ml}$) for

40–60 min before the patch-clamp recordings. However, mAB-C1qBP treatment did not affect TLQP21-induced currents (Fig. 3*B,C*). We therefore conclude that TLQP21 evokes outwardly rectifying potassium currents in microglial cells via C3aR1, but not via C1qBP.

We then investigated whether the TLQP21-evoked decrease of microglial P2Y responses is mediated by either C3aR1 or C1qBP. The blockade of C3aR1 did not prevent the TLQP21-induced inhibition of ATP-evoked outward potassium currents. When TLQP21 (100 nM) was applied together with SB290157 (1 μ M), subsequent ATP-evoked outward currents were still significantly reduced ($G_{\text{out}} = 10.4 \pm 7.3$ pS/pF; $n = 9$; $p = 0.0003$ to control ATP responses; Fig. 3*D,E*), indicating that SB290157 does not prevent the impact of TLQP21 on ATP-induced currents. To test for the involvement of C1qBP, we preincubated microglia with mAB-C1qBP (3 μ g/ml) for 40–60 min before recording. Interestingly, after that treatment, we observed a complete recovery of P2Y responses ($G_{\text{out}} = 113.3 \pm 14.4$ pS/pF; $n = 9$; $p = 0.1289$ to control ATP responses; Fig. 3*D,E*), indicating that the impairment of microglial purinergic responses by TLQP21 is mediated by signaling through C1qBP, but not C3aR1.

TLQP21 induces intracellular calcium elevations in microglia via C3aR1

We tested the effects of TLQP21 (1, 10, and 100 nM) on intracellular Ca^{2+} levels in neonatal cultured microglia. TLQP21 was applied for 30 s on microglia loaded with Fluo-4 (Fig. 4*A*). In accordance to Korvers et al. (2016), microglia exhibited a moderate level of spontaneous Ca^{2+} elevations under basal conditions, resulting in an overall basal responsiveness of $10.8 \pm 1.7\%$ during a recording period of 30 s ($n = 4909$ cells/44 exp). When 1, 10, or 100 nM TLQP21 was applied, on average $56.9 \pm 10.0\%$ ($p = 0.0011$; $n = 1401$ cells/10 exp), $39.1 \pm 10.2\%$ ($p = 0.0482$; $n = 100$ cells/5 exp), and $44.8 \pm 10.8\%$ ($p = 0.0056$; $n = 1267$ cells/14 exp) of the cells responded, indicating that TLQP21 increases intracellular calcium levels in microglia (Fig. 4*B–D*). Intracellular Ca^{2+} increases upon TLQP21 had diverse time courses ranging from a constant increase over the whole application period to periodically occurring transients, which sometimes even persisted after TLQP21 washout. We quantified the maximum amplitudes of microglial TLQP21 responses and normalized them to the amplitudes evoked by ATP (500 μ M), which were measured at the end of each experiment. As shown in Figure 4*D*, amplitudes in the presence of 1, 10, and 100 nM TLQP21 were $25.5 \pm 8.7\%$ ($p = 0.0251$; $n = 1401$ cells/10 exp), $36.6 \pm 10.3\%$ ($p = 0.0274$; $n = 100$ cells/5 exp), and $37.1 \pm 8.9\%$ ($p = 0.0018$; $n = 1267$ cells/14 exp),

Figure 4. TLQP21 induces intracellular calcium elevations in microglia via C3aR1. *A*, Left, Cultured neonatal microglia were loaded with Fluo4 to measure cytosolic Ca^{2+} level changes fluorometrically. The image shows the Fluo4 fluorescence. Right, Representative Ca^{2+} imaging experiment, corresponding to the image shown on the left. Traces are superimposed from 24 ROIs, respective microglial cells; 100 nM TLQP21 and 500 μ M ATP were applied as indicated by the bars. *B*, Overlay of all microglial Ca^{2+} traces obtained upon 1 nM (left) and 100 nM (middle left) TLQP21, as well as upon 100 nM TLQP21 in the presence of either 1 μ M SB290157 (middle right) or mAB-C1qBP (right). *C*, Summary of percentage of microglia responding upon TLQP21 at different concentrations and in the absence and presence of SB290157 or mAB-C1qBP. As microglia display spontaneous Ca^{2+} elevations (Korvers et al., 2016), responding microglia in the absence of TLQP21 are also summarized ("0 nM TLQP21"). *D*, Summary of the amplitudes evoked by TLQP21 at different concentrations in the absence and presence of SB290157 or mAB-C1qBP. Amplitude of each cell was normalized to the amplitude in the presence of ATP. As microglia display spontaneous Ca^{2+} elevations (Korvers et al., 2016), basal amplitudes were also summarized ("0 nM TLQP21"). *E*, Overlay of microglial Ca^{2+} responses upon 500 μ M ATP with or without prior application of 100 nM TLQP21. *F*, *G*, TLQP21 application did neither alter the percentage of primary microglia responding to subsequent ATP applications (*F*) nor the amplitude of the ATP responses (*G*). * $p < 0.05$. ** $p < 0.01$. *** $p < 0.001$. n.s., Not significant ($p > 0.05$).

respectively, and therefore significantly larger than baseline Ca^{2+} fluctuations ($2.1 \pm 1.7\%$, $n = 4909$ cells/44 exp). We also tested the effects of the C3aR1 antagonist SB290157 (1 μ M) on TLQP21-evoked Ca^{2+} responses in microglia. We found that only $13.2 \pm 5.7\%$ of cells responded to 100 nM TLQP21 in the presence of SB290157 ($n = 2141$ cells/15 exp), which was significantly different from 100 nM TLQP21 alone ($p = 0.0142$), but not from baseline ($p = 0.6600$). The maximal Ca^{2+} amplitudes upon 100 nM TLQP21 in the presence of SB290157 ($12.2 \pm 3.8\%$; $p = 0.0254$; $n = 2141$ cells/15 exp) were significantly smaller than in the absence of SB290157 ($37.1 \pm 9.0\%$; $n = 1267$ cells/14 exp; $p = 0.0237$), and not different from control conditions ($2.1 \pm 1.7\%$; $n = 4909$ cells/44 exp; $p = 0.5960$). We also tested the effect of C1qBP blockade on microglial Ca^{2+} responses upon 100 nM

Figure 5. TLQP21 affects microglial phagocytic activity. **A**, Phagocytosis assay *in situ*. Representative confocal image (left) of Iba1-stained microglia (red) after 60 min incubation with latex beads (blue) performed on a cortical brain slice from a 14 week BL6 mouse. Right, 3D reconstruction of Iba1-positive microglia is shown with automatically counted phagocytosed beads (shown in white and indicated by arrows). Scale bar, 50 μ m. Inset, Magnification of a 3D-rendered microglial cell that incorporates a latex bead. Color code as in the large images. Scale bar, 10 μ m. **B**, Summary of microglial phagocytosis in cortical brain slices (*in situ*). Control phagocytosis in the absence of UDP (–) was decreased by preincubation with TLQP21. This decrease was rescued by C1qBP blockade (mAB-C1qBP) but not affected by C3aR1 blockade (SB290157). In the presence of 100 μ M UDP (+), phagocytosis was stimulated under control conditions, an effect that was prevented by pretreatment with TLQP21 (100 nM). C1qBP blockade (mAB-C1qBP), but not C3aR1 blockade (SB290157) during TLQP21 incubation restored UDP stimulation of microglial phagocytosis. The significance level above the bars refers to the control value with or without UDP. **C**, To determine phagocytic activity in culture, primary microglia were incubated with fluorescent microbeads (YFP) subsequent to preincubation with TLQP21 (100 nM) or PBS (Control) for 30 min, fixed, and stained for Iba1. Representative images for these conditions are shown. **D**, Microglial phagocytic indices (mean $\pm$ SEM) under control- and UDP-stimulating conditions. TLQP21 enhanced microglial phagocytosis under control conditions (–), and this stimulation was blocked by coinubation with C3aR1 antagonist SB290157. Preincubation with TLQP21 decreased the UDP-induced stimulation of microglial phagocytosis (+), which was not prevented by C3aR1 blockade (SB290157). The significance level above the bars refers to the control value with or without UDP. * p < 0.05, *** p < 0.001. n.s., Not significant (p > 0.05). See Figure S-1.

TLQP21. The incubation of microglia for 30 min with mAB-C1qBP (3 μ g/ml) did not lead to a decrease but even to an increase of TLQP21 responses ($89.0 \pm 8.4\%$, $n = 171$ cells/7 exp; $p = 0.0008$ compared with 100 nM TLQP21) and relative amplitudes ($72.7 \pm 13.0\%$; $p = 0.0056$ compared with 100 nM TLQP21). Together, these data show that TLQP21 evokes intracellular Ca^{2+} elevations via C3aR1 activation.

We additionally looked at the impact of TLQP21 application on subsequent ATP-evoked Ca^{2+} responses (Fig. 4E,F). However, no differences were found in either the percentage of microglia responding to 500 μ M ATP or in the amplitude of ATP-induced cytosolic Ca^{2+} increases. Thus, TLQP21 attenuates microglial ATP-evoked membrane currents but not ATP-evoked intracellular Ca^{2+} elevations.

TLQP21 differentially affects the phagocytic activity *in vitro* and *in situ*

To study the effect of TLQP21 on P2Y-mediated functions in microglia, we analyzed UDP-stimulated phagocytosis *in situ*. It was previously shown that microglial phagocytosis is stimulated through P2Y₆R activation by UDP (Koizumi et al., 2007; Xu et al., 2016; Wendt et al., 2017). We incubated acute brain slices from male C57BL/6J mice (14 weeks) for 60 min with fluorescent latex beads and subsequently stained for labeled microglia with anti-Iba1. Confocal imaging and 3D reconstruction (Fig. 5A) were

used to quantify the number of beads that were incorporated into a 3D-rendered Iba1-labeled volume, which allowed us to calculate the phagocytic index of microglia (see Materials and Methods). As shown in Figure 5B, baseline microglial phagocytosis (1.00 ± 0.06 ; $n = 21$) was indeed significantly increased when UDP (100 μ M) was coapplied together with the beads (1.67 ± 0.1 ; $n = 21$; $p < 0.0001$). Interestingly, preincubation (i.e., before the incubation with the beads) of the slices for 60 min with 100 nM TLQP21 decreased the phagocytic activity of microglia (0.66 ± 0.05 ; $n = 21$; $p = 0.0001$), suggesting that a downregulation of microglial purinergic signaling is affecting the basal phagocytic activity. Furthermore, UDP stimulation of microglia completely failed after TLQP21 treatment (0.74 ± 0.05 ; $n = 21$; $p = 0.0001$). Preincubation of the slices with TLQP21 (100 μ M) + SB290157 (1 μ M) did not alter microglial phagocytosis compared with TLQP21 preincubation alone (0.81 ± 0.08 ; $n = 12$; $p = 0.06$), indicating that the impairment of microglial purinergic signaling by TLQP21 occurs independently of C3aR1 and confirming again the lack of functional C3aR1 receptors on microglia *in situ*. To check for the involvement of C1qBP, slices were preincubated with TLQP21 + mAB-C1qBP. This treatment did rescue both the TLQP21-dependent decline in basal phagocytosis (Fig. 5B) as well as the TLQP21-derived impairment of UDP-stimulated phagocytosis ($1.72 \pm$

0.15 ; $n = 12$; $p < 0.0001$ compared with Control/TLQP21; Fig. 5B). Thus, TLQP21 impairs microglial phagocytic activity *in situ* in a C1qBP-dependent fashion.

We also tested whether TLQP21 affects microglial phagocytic activity and UDP stimulation of phagocytosis *in vitro*. Consistent with previous reports (Koizumi et al., 2007), 30 min incubation of microglia with 100 μ M UDP significantly increased their phagocytic activity (from 19.3 ± 0.7 to 23.9 ± 0.8 ; $n = 36$; $p = 0.0016$; Fig. 5C,D). We preincubated microglia for 30 min with TLQP21 (100 nM) and quantified their phagocytic activity. TLQP21 treatment caused a significant increase in microglial phagocytic activity to 24.6 ± 0.9 ($n = 34$; $p = 0.0032$ compared with control), indicating that TLQP21 directly stimulated phagocytosis. The UDP-evoked stimulation of microglial phagocytosis was, however, prevented by a 30 min pretreatment with 100 μ M TLQP21 (16.6 ± 0.6 ; $n = 36$; $p < 0.0001$ compared with UDP without pretreatment), and this could not be restored by C3aR1 blockade (17.4 ± 0.9 ; $n = 33$; $p < 0.0001$ compared with UDP without pretreatment). Thus, in culture, TLQP21 has two effects: a direct stimulation of phagocytic activity and an impairment of the purinergic control of microglial phagocytosis.

To confirm that TLQP21 not only affects ATP mediated signaling, but also UDP-dependent signaling, we used the patch-

clamp technique and tested the effect of 100 nM TLQP21 on subsequent UDP-mediated membrane currents and Ca^{2+} responses (Fig. 5-1A). As for 10 μM ATP (see above), also UDP (100 μM) reliably evoked outwardly rectifying membrane currents ($G_{\text{out}} = 8.2 \pm 2.0$ pS/pF; $n = 10$; Fig. 5-1B), which reversed close to the Nernst potential for K^+ (-82.2 ± 8.3 mV; $n = 10$). However, when 100 nM TLQP21 was applied 5 min before UDP application, UDP-evoked outward currents were significantly smaller ($G_{\text{out}} = 1.4 \pm 2.9$ pS/pF; $n = 8$; $p = 0.0357$; Fig. 5-1B).

TLQP21 triggers chemotaxis and inhibits ATP-induced migration

We studied the impact of TLQP21 on microglial migration and first tested whether there is chemotaxis toward TLQP21. We used an agarose spot assay, in which the agarose was mixed with three different concentrations of TLQP21 to create a gradient from the agarose spot to the surrounding medium (Fig. 6A). After a 3 h incubation, 10 and 100 nM TLQP21 significantly increased the percentage of microglia migrating into the agarose area compared with control spots without TLQP21 in the same well to 3.1 ± 0.5 and to 2.5 ± 0.4 , respectively ($p = 0.0008$, 15–23 spots from four independent biological replicates). Migration into spots containing 1 nM TLQP21 was only 2.1 ± 0.3 -fold higher than into PBS-containing spots (not significant). We verified these results using the Boyden chamber assay (Fig. 6-1A). TLQP21 at concentrations of 1, 10, or 100 nM were added in the bottom of the Boyden chamber to generate a TLQP21 gradient. The percentage of cells that migrated to the bottom of the chamber through the membrane within 3 h was quantified in relation to a control (no TLQP21). There was a significant increase of cells in the lower well with 100 nM TLQP21 (3.0 ± 0.5 -fold increase compared with control; $p = 0.0006$; $n = 4$), whereas 1 and 10 nM did not significantly differ from control. There was no chemotaxis toward a gradient of scrambled peptide (100 nM) ($p = 0.6000$; Fig. 6-1A), excluding unspecific peptide effects on microglial migration.

We also tested whether TLQP21 influences microglial undirected motility by ablating the concentration gradient in the agarose spot experiments (Fig. 6A). TLQP21 at concentrations of 10 and 100 nM was added to both the spot and the medium, thus disseminating the gradient. This did not increase microglial migration (1.0 ± 0.1 ; $p = 0.3863$; $n = 6$ for 10 nM TLQP21 spots and 1.0 ± 0.3 ; $p = 0.1139$; $n = 8$ for 100 nM TLQP21 spots vs PBS-containing spots), indicating that TLQP21 does not increase microglial motility. This finding was confirmed in Boyden chamber assays when applying TLQP21 in both upper and lower chamber, thus with no gradient. Neither 10 nM nor 100 nM TLQP21 led to a significant increase in microglial motility ($p = 0.8100$; Fig. 6-1A). The scratch wound assay was used as another general cellular motility assay: TLQP21 was added to the culture medium and the number of microglial cells, which moved toward the cell-free area within 3 h was compared with control (Fig. 6-1B). At 1, 10, and 100 nM TLQP21, the number of cells in

Figure 6. Effect of TLQP21 on microglial migration. **A**, Agarose spot assay testing microglial migration toward TLQP21. There was a concentration-dependent preference for microglial cells to migrate to the 100 nM TLQP21-containing spots as shown in the images on the left. Right, Average migration toward TLQP21 relative to the PBS control are summarized for three different TLQP21 concentrations and in the presence of the C3aR1 inhibitor SB290157, which was abolished in the TLQP21 response. In addition, average data for a disseminated (no) gradient are also given at 10 and 100 nM TLQP21. The significance level indicated above each bar refers to the PBS control. **B**, Agarose spot assay testing microglial migration toward ATP. Microglia were plated onto a glass coverslip with agarose spots containing ATP (500 μM). Sample images are shown on the left. Right, Average migration toward ATP relative to the PBS control are summarized. Microglia preferred ATP-containing spots (control), and this preference was abolished by incubation with 100 nM TLQP21. Blockade of C3aR1 by SB290157 did not rescue the loss of ATP preference after TLQP21 treatment, whereas C1qBP inhibition partially restored microglial chemotaxis toward ATP. *** $p < 0.001$. n.s., Not significant ($p > 0.05$). See Figure 6-1.

the cell-free area was 1.1 ± 0.3 -, 1.5 ± 0.5 -, and 1.8 ± 0.2 -fold compared with control and therefore not significantly changed ($n = 9$; Fig. 6-1B). This again validates our previous findings that TLQP21 mediates microglial chemotaxis but does not influence microglial motility.

Microglia migration is stimulated by purinergic signaling. We thus aimed to study whether TLQP21 would interfere with ATP-induced migration (Fig. 6B), and performed an agarose spot assay. We first quantified the migration toward ATP under control conditions: ATP (1 mM) and control (PBS) spots were placed in dishes together with untreated microglial cells. During 3 h of incubation time, microglia migrated preferentially toward the ATP-containing spots (7.1 ± 0.7 -fold compared with PBS-containing spots; $p < 0.0001$; $n = 16$). Intriguingly, when microglia were incubated with 100 nM TLQP21, the preference for ATP-containing spots after 3 h was eliminated. The average preference for ATP-containing spots was only 0.55 ± 0.03 after TLQP21 treatment and therefore significantly smaller than in control experiments without TLQP21 ($p = 0.0001$; $n = 45$). Thus, TLQP21 impairs microglial chemotaxis toward ATP. We finally applied agarose spot assays to test for the involvement of C3aR1 and C1qBP in the TLQP21-mediated effects on microglial chemotaxis. Interestingly, the blockade of C3aR1 by SB290157 (1 μM) significantly reduced microglial migration toward TLQP21 (1.5 ± 0.1 -fold compared with PBS spots; $p = 0.0047$; $n = 9$; Fig. 6A) but did not restore the TLQP21-mediated loss in migration toward ATP (0.56 ± 1.27 relative to PBS spots; $n = 11$; Fig. 6B). On the other hand, incubating the cells with a combination of 100 nM TLQP21 and mAB-C1qBP (1.5 $\mu\text{g}/\text{ml}$) restored the migration of microglial cells toward ATP-containing agarose spots (2.5 ± 0.22 relative to PBS; $p < 0.0001$; $n = 11$; Fig. 6B). We conclude that microglial chemotaxis toward TLQP21

Figure 7. TLQP21 decreases microglial-directed process movement in a C1qBP-dependent manner. **A**, Representative pictures of injury-induced process movement of EGFP-positive microglia in the cortex of acute brain slices from MacGreen mice under control conditions (left panels) and after preincubation with 100 nM TLQP21 (right panels). Acute injury was induced by a laser lesion (red asterisk), and microglial responses were observed for 30 min. Images were taken using 2-photon microscopy at 0 min (top, directly after setting the laser lesion) and 25 min later (bottom). Scale bars, 20 μ m. **B**, Quantitative analysis of injury-induced process motility in control conditions, after preincubation with TLQP21 (100 nM) or TLQP21 (100 nM) + SB290157 (1 μ M). The microglial-directed process movement was significantly slower after pretreatment with TLQP21 (100 nM), which could not be rescued by blockade of C3aR1. Green and blue asterisks indicate the Tukey comparisons “Control” versus “after TLQP21” and “Control” versus “after TLQP21 + SB290157,” respectively. The conditions “after TLQP21” and “after TLQP21 + SB290157” were not significantly different. **C**, Same as in **B**, but using mAB-C1qBP (3 μ g/ml) instead of SB290157. C1qBP blockade rescued the TLQP21-induced reduction in directed process motility. Green and red asterisks indicate the Tukey comparisons “Control” versus “after TLQP21” and “after TLQP21” versus “after TLQP21 + mAB-C1qBP,” respectively. The conditions “Control” and “after TLQP21 + mAB-C1qBP” were not significantly different. * $p < 0.05$.

depends on C3aR1, and the TLQP21-mediated loss in chemotaxis toward ATP depends on C1qBP.

TLQP21 decreases microglial process movement toward a microlesion

We finally investigated the chemotactic movement of microglial processes that depends on extracellular ATP/ADP and signaling through P2RY₁₂ (Davalos et al., 2005; Nimmerjahn et al., 2005; Haynes et al., 2006). As TLQP21 affects microglial purinergic signaling, we expected a decrease in processes movement. We used MacGreen mice, which express an EGFP transgene under the *Csf1R1* promoter to identify microglial cells (Sasmono et al., 2003). The movement of microglial processes was quantified by determining the fluorescence distribution within concentric circles (45 and 240 μ m; Fig. 6A) around the lesion site. During the 30 min recording time after the laser lesion, the microglial processes moved toward the lesion site, resulting in an increase in fluorescence in the areas closer to the lesion site, which then was quantified as described in Materials and Methods (40.9 ± 3.6 , $n = 16$; Fig. 7A,B) under control conditions. The preincubation of brain slices with TLQP21 (100 nM) for 60 min before the induction of the laser lesion (Fig. 7A–C) led indeed to a reduction of these responses to 28.7 ± 4.0 ($n = 12$, $p = 0.0370$), indicating a TLQP21-mediated decline of microglial purinergic responses. This impairment could not be restored by the C3aR1 inhibitor SB290157 (26.9 ± 3.0 ; $n = 13$, $p = 0.0318$ to control; $p = 0.9806$ to TLQP21; Fig. 7B). However, blockade of C1qBP by

preincubating the slices with TLQP21 and mAB-C1qBP led to a rescue of microglial process movement toward the lesion site that was not significantly different from control conditions (44.7 ± 5.1 ; $n = 13$, $p = 0.5303$ to control; $p = 0.0008$ to TLQP21; Fig. 7C). These experiments provide further evidence that TLQP21 acts via C1qBP to downregulate purinergic signaling in microglia.

Discussion

In the present study, we demonstrate that the VGF-derived peptide TLQP21 affects microglial function via two distinct pathways linked to distinct microglial features: (1) via a C1qBP-dependent pathway resulting in a downregulation of purinergic signaling through metabotropic P2Y receptors; and (2) via a C3aR1-dependent pathway activating membrane currents, Ca^{2+} responses, and stimulating migration and phagocytic activity. The C1qBP-dependent impairment of purinergic responses results in a reduction of membrane currents evoked by metabotropic P2Y receptors, chemoattractance by ATP, and the stimulation of microglial phagocytosis by UDP. Intriguingly, purinergic responses were affected even minutes after washout of TLQP21, indicating that C1qBP-dependent signaling results in a long-term change in microglial properties.

To our knowledge, C1qBP is the first receptor that has a long-term modulating effect on microglial purinergic responses.

Previous studies on TLQP21 and its receptors described Ca^{2+} responses in microglia (Chen et al., 2013; Hannedouche et al., 2013; Molteni et al., 2017). In these studies and in ours, the ATP-induced Ca^{2+} responses were not attenuated by TLQP21 (Fig. 4). In the present study, we found that TLQP21 also acts, in addition to C1qBP, on another receptor, the G-protein-coupled complement receptor C3aR1. C3aR1 activation by TLQP21 triggered outwardly rectifying K^{+} currents, intracellular Ca^{2+} elevations, and C3aR1 was found to be responsible for chemotaxis and TLQP21 stimulation of phagocytic activity. However, all these stimulating effects of TLQP21 were only found in primary cultured microglia but not *in situ*, consistent with the finding that the robust C3aR1 protein expression in cultures was lacking in freshly isolated microglia. This intriguing difference might arise either from the fact that our primary cultures are derived from neonatal mice, whereas freshly isolated *in situ* microglia in this study are adult or from the culture environment that more mimics a pathologic situation. A previous proteomic study also detected C3aR1 protein only in cultured but not freshly isolated microglia (Sharma et al., 2015). Surprisingly, on the mRNA level, recent transcriptomic studies report robust expression of the *C3ar1* gene also in freshly isolated microglia (Hickman et al., 2013; Tabula Muris Consortium, 2018), suggesting that *C3ar1* mRNA is either more prevalent or easier to detect than the protein.

Looking at nonphysiological states, microglial *C3ar1* mRNA levels were found to be increased upon aging and under patho-

logic conditions, including dementia, AD, traumatic brain injury, and epilepsy (Hickman et al., 2013; Bodea et al., 2014; Zhao et al., 2018). This raises the intriguing possibility that functional C3aR1 protein expression could be induced by microglia activation, and that the stimulatory effects of TLQP21 *in vivo* become significant under disease conditions only. Indeed, recent studies demonstrated ameliorating effects in the tau pathology of an animal model of AD by deletion of *C3aR1* (Litvinchuk et al., 2018) and a reduction in inflammatory microglial density after stroke by intracortical injection of SB290157 (Surugiu et al., 2019), the same C3aR1 blocker that was used in our study.

There are several studies demonstrating a correlation of VGF-derived peptides and brain physiology, suggesting the intriguing possibility that microglial features are modulated by signaling through these peptides *in vivo*. The concentration of VGF peptides in the CSF is in the picomolar range (van Steenoven et al., 2019), which is lower by a factor of 10^4 compared with the concentration we have used in the present study. The CSF concentration, however, most likely does not reflect the concentration in the brain parenchyma. Since VGF is preferentially expressed by neurons (Zhang et al., 2014), local concentrations of VGF and its peptides may reach levels as high as the ones used in our study, in particular at neuronal release sites.

We have recently demonstrated that microglial purinergic signaling is impaired in mouse models of AD (Wendt et al., 2017). Both functions, which are affected by pretreatment with the VGF-derived peptide TLQP21 in brain tissue, namely, the phagocytic activity and the process motility stimulated by purinergic signaling, are also impaired in these mouse models. Indeed, VGF is suggested as a potential biomarker for AD as VGF-derived peptides were found to be significantly decreased in the CSF of AD patients (Carrette et al., 2003; Hendrickson et al., 2015; Spellman et al., 2015).

TLQP21 is one of many bioactive peptides derived from post-translational cleavage of VGF. Recent evidence suggests a comprehensive role of TLQP21 in neuronal network homeostasis and demonstrates the involvement of TLQP21 in many brain diseases, including psychiatric, neurodegenerative, and neuroinflammatory diseases (Alder et al., 2003; Severini et al., 2008; Sato et al., 2012; Lin et al., 2015; Sakamoto et al., 2015). Microglia, as the resident immune cells of the CNS, play an important role in any kind of brain disease (Wolf et al., 2017), and our data indicate a mechanistic link between TLQP21 and the attenuation (via C1qBP) or stimulation (via C3aR1) of microglial functions in health and disease. Microglial C3aR1 or C1qBP might therefore be interesting targets for clinical therapies.

References

- Aguilar E, Pineda R, Gaytán F, Sánchez-Garrido MA, Romero M, Romero Ruiz A, Ruiz-Pino F, Tena-Sempere M, Pinilla L (2013) Characterization of the reproductive effects of the Vgf-derived peptide TLQP-21 in female rats: *in vivo* and *in vitro* studies. *Neuroendocrinology* 98:38–50.
- Alder J, Thakker-Varia S, Bangasser DA, Kuroiwa M, Plummer MR, Shors TJ, Black IB (2003) Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. *J Neurosci* 23:10800–10808.
- Arbibe L, Mira JP, Teusch N, Kline L, Guha M, Mackman N, Godowski PJ, Ulevitch RJ, Knaus UG (2000) Toll-like receptor 2-mediated NF- κ B activation requires a Rac1-dependent pathway. *Nat Immunol* 1:533–540.
- Bartolomucci A, La Corte G, Possenti R, Locatelli V, Rigamonti AE, Torsello A, Bresciani E, Bulgarelli I, Rizzi R, Pavone F, D'Amato FR, Severini C, Mignogna G, Giorgi A, Schininà ME, Elia G, Brancia C, Ferri GL, Conti R, Ciani B, et al. (2006) TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. *Proc Natl Acad Sci U S A* 103:14584–14589.
- Bodea LG, Wang Y, Linnartz-Gerlach B, Kopatz J, Sinkkonen L, Musgrove R, Kaoma T, Muller A, Vallar L, Di Monte DA, Balling R, Neumann H (2014) Neurodegeneration by activation of the microglial complement-phagosome pathway. *J Neurosci* 34:8546–8556.
- Boucsein C, Kettenmann H, Nolte C (2000) Electrophysiological properties of microglial cells in normal and pathologic rat brain slices. *Eur J Neurosci* 12:2049–2058.
- Boucsein C, Zacharias R, Färber K, Pavlovic S, Hanisch UK, Kettenmann H (2003) Purinergic receptors on microglial cells: functional expression in acute brain slices and modulation of microglial activation *in vitro*. *Eur J Neurosci* 17:2267–2276.
- Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsparger T, Dake B, Wu PM, Doykan CE, Fanek Z, Liu L, Chen Z, Rothstein JD, Ransohoff RM, Gygi SP, Antel JP, Weiner HL (2014) Identification of a unique TGF- β -dependent molecular and functional signature in microglia. *Nat Neurosci* 17:131–143.
- Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez JC (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. *Proteomics* 3:1486–1494.
- Chen YC, Pristérá A, Ayub M, Swanwick RS, Karu K, Hamada Y, Rice AS, Okuse K (2013) Identification of a receptor for neuropeptide VGF and its role in neuropathic pain. *J Biol Chem* 288:34638–34646.
- Cocco C, Corda G, Lisci C, Noli B, Carta M, Brancia C, Manca E, Masala C, Marrosu F, Solla P, Manconi B, Bongioanni P, Ferri GL (2020) VGF peptides as novel biomarkers in Parkinson's disease. *Cell Tissue Res* 379:93–107.
- Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol* 26:1367–1372.
- Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB (2005) ATP mediates rapid microglial response to local brain injury *in vivo*. *Nat Neurosci* 8:752–758.
- Dissing-Olesen L, LeDue JM, Rungta RL, Hefendehl JK, Choi HB, MacVicar BA (2014) Activation of neuronal NMDA receptors triggers transient ATP-mediated microglial process outgrowth. *J Neurosci* 34:10511–10527.
- Fairbanks CA, Peterson CD, Speltz RH, Riedl MS, Kitto KF, Dykstra JA, Braun PD, Sadahiro M, Salton SR, Vulchanova L (2014) The VGF-derived peptide TLQP-21 contributes to inflammatory and nerve injury-induced hypersensitivity. *Pain* 155:1229–1237.
- Fargali S, Garcia AL, Sadahiro M, Jiang C, Janssen WG, Lin WJ, Cogliani V, Elste A, Mortillo S, Cero C, Veitenheimer B, Graiani G, Pasinetti GM, Mahata SK, Osborn JW, Huntley GW, Phillips GR, Benson DL, Bartolomucci A, Salton SR (2014) The granin VGF promotes genesis of secretory vesicles, and regulates circulating catecholamine levels and blood pressure. *FASEB J* 28:2120–2133.
- Hannedouche S, Beck V, Leighton-Davies J, Beibel M, Roma G, Oakeley EJ, Lannoy V, Bernard J, Hamon J, Barbieri S, Preuss I, Lasbennes MC, Sailer AW, Suply T, Seuwen K, Parker CN, Bassilana F (2013) Identification of the C3a receptor (C3aR1) as the target of the VGF-derived peptide TLQP-21 in rodent cells. *J Biol Chem* 288:27434–27443.
- Haynes SE, Höllopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, Julius D (2006) The P2Y₁₂ receptor regulates microglial activation by extracellular nucleotides. *Nat Neurosci* 9:1512–1519.
- Hendrickson RC, Lee AY, Song Q, Liaw A, Wiener M, Paweletz CP, Seeburger JL, Li J, Meng F, Deyanova EG, Mazur MT, Settlege RE, Zhao X, Southwick K, Du Y, Holder D, Sachs JR, Laterza OF, Dallob A, Chappell DL, et al. (2015) High resolution discovery proteomics reveals candidate disease progression markers of Alzheimer's disease in human cerebrospinal fluid. *PLoS One* 10:e0135365.
- Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, El Khoury J (2013) The microglial sensome revealed by direct RNA sequencing. *Nat Neurosci* 16:1896–1905.
- Jiang C, Lin WJ, Labonté B, Tammings CA, Turecki G, Nestler EJ, Russo SJ, Salton SR (2019) VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine. *Neuropsychopharmacology* 44:971–981.
- Kanashova T, Popp O, Orasche J, Karg E, Harndorf H, Stengel B, Sklorz M, Streibel T, Zimmermann R, Dittmar G (2015) Differential proteomic analysis of mouse macrophages exposed to adsorbate-loaded heavy fuel oil derived combustion particles using an automated sample-preparation workflow. *Anal Bioanal Chem* 407:5965–5976.
- Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011) Physiology of microglia. *Physiol Rev* 91:461–553.

- Klos A, Wende E, Wareham KJ, Monk PN (2013) International union of basic and clinical pharmacology [corrected]. LXXXVII: complement peptide C5a, C4a, and C3a receptors. *Pharmacol Rev* 65:500–543.
- Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K, Tsuda M, Joshi BV, Jacobson KA, Kohsaka S, Inoue K (2007) UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. *Nature* 446:1091–1095.
- Korvers L, de Andrade Costa A, Mersch M, Matyash V, Kettenmann H, Semtner M (2016) Spontaneous Ca^{2+} transients in mouse microglia. *Cell Calcium* 60:396–406.
- Lewis JE, Brameld JM, Jethwa PH (2015) Neuroendocrine role for VGF. *Front Endocrinol (Lausanne)* 6:3.
- Lin WJ, Jiang C, Sadahiro M, Bozdagi O, Vulchanova L, Alberini CM, Salton SR (2015) VGF and its C-terminal peptide TLQP-62 regulate memory formation in hippocampus via a BDNF-TrkB-dependent mechanism. *J Neurosci* 35:10343–10356.
- Litvinchuk A, Wan YW, Swartzlander DB, Chen F, Cole A, Propson NE, Wang Q, Zhang B, Liu Z, Zheng H (2018) Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease. *Neuron* 100:1337–1353.e5.
- Llano DA, Devanarayan P, Devanarayan V (2019) VGF in cerebrospinal fluid combined with conventional biomarkers enhances prediction of conversion from MCI to AD. *Alzheimer Dis Assoc Disord* 33:307–314.
- Madry C, Kyrargyri V, Arancibia-Carcamo IL, Jolivet R, Kohsaka S, Bryan RM, Attwell D (2018) Microglial ramification, surveillance, and interleukin-1 β release are regulated by the two-pore domain K(+) channel THIK-1. *Neuron* 97:299–312.e296.
- Molteni L, Rizzi L, Bresciani E, Possenti R, Petrocchi Passeri P, Ghè C, Muccioli G, Fehrentz JA, Verdié P, Martínez J, Omeljaniuk RJ, Biagini G, Binda A, Rivolta I, Locatelli V, Torsello A (2017) Pharmacological and biochemical characterization of TLQP-21 activation of a binding site on CHO cells. *Front Pharmacol* 8:167.
- Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. *Science* 308:1314–1318.
- Ousingsawat J, Wanitchakool P, Kmit A, Romao AM, Jantarajit W, Schreiber R, Kunzelmann K (2015) Anoctamin 6 mediates effects essential for innate immunity downstream of P2X7 receptors in macrophages. *Nat Commun* 6:6245.
- Pannell M, Meier MA, Szulzewsky F, Matyash V, Endres M, Kronenberg G, Prinz V, Waiczies S, Wolf SA, Kettenmann H (2016) The subpopulation of microglia expressing functional muscarinic acetylcholine receptors expands in stroke and Alzheimer's disease. *Brain Struct Funct* 221:1157–1172.
- Peerschke EI, Ghebrehewet B (2007) The contribution of gC1qR/p33 in infection and inflammation. *Immunobiology* 212:333–342.
- Pinilla L, Pineda R, Gaytán F, Romero M, García-Galiano D, Sánchez-Garrido MA, Ruiz-Pino F, Tena-Sempere M, Aguilar E (2011) Characterization of the reproductive effects of the anorexigenic VGF-derived peptide TLQP-21: in vivo and in vitro studies in male rats. *Am J Physiol Endocrinol Metab* 300:E837–E847.
- Possenti R, Muccioli G, Petrocchi P, Cero C, Cabassi A, Vulchanova L, Riedl MS, Manieri M, Frontini A, Giordano A, Cinti S, Govoni P, Graiani G, Quaini F, Ghe C, Bresciani E, Bulgarelli I, Torsello A, Locatelli V, Sanghez V, et al. (2012) Characterization of a novel peripheral pro-lipolytic mechanism in mice: role of VGF-derived peptide TLQP-21. *Biochem J* 441:511–522.
- Rappasilber J, Mann M, Ishihama Y (2007) Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. *Nat Protoc* 2:1896–1906.
- Rizzi R, Bartolomucci A, Moles A, D'Amato F, Sacerdote P, Levi A, La Corte G, Ciotti MT, Possenti R, Pavone F (2008) The VGF-derived peptide TLQP-21: a new modulatory peptide for inflammatory pain. *Neurosci Lett* 441:129–133.
- Sakamoto M, Miyazaki Y, Kitajo K, Yamaguchi A (2015) VGF, which is induced transcriptionally in stroke brain, enhances neurite extension and confers protection against ischemia in vitro. *Transl Stroke Res* 6:301–308.
- Sarkar SN, Peters KL, Elco CP, Sakamoto S, Pal S, Sen GC (2004) Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. *Nat Struct Mol Biol* 11:1060–1067.
- Sasmono RT, Oceandy D, Pollard JW, Tong W, Pavli P, Wainwright BJ, Ostrowski MC, Himes SR, Hume DA (2003) A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. *Blood* 101:1155–1163.
- Sasmono RT, Williams E (2012) Generation and characterization of MacGreen mice, the Cx36-EGFP transgenic mice. *Methods Mol Biol* 844:157–176.
- Sato H, Fukutani Y, Yamamoto Y, Tataru E, Takemoto M, Shimamura K, Yamamoto N (2012) Thalamus-derived molecules promote survival and dendritic growth of developing cortical neurons. *J Neurosci* 32:15388–15402.
- Severini C, Ciotti MT, Biondini L, Quaresima S, Rinaldi AM, Levi A, Frank C, Possenti R (2008) TLQP-21, a neuroendocrine VGF-derived peptide, prevents cerebellar granule cells death induced by serum and potassium deprivation. *J Neurochem* 104:534–544.
- Severini C, La Corte G, Improta G, Broccardo M, Agostini S, Petrella C, Sibilia V, Pagani F, Guidobono F, Bulgarelli I, Ferri GL, Brancia C, Rinaldi AM, Levi A, Possenti R (2009) *In vitro* and *in vivo* pharmacological role of TLQP-21, a VGF-derived peptide, in the regulation of rat gastric motor functions. *Br J Pharmacol* 157:984–993.
- Sharma K, Schmitt S, Bergner CG, Tyanova S, Kannaiyan N, Manrique-Hoyos N, Kongi K, Cantuti L, Hanisch UK, Philips MA, Rossner MJ, Mann M, Simons M (2015) Cell type- and brain region-resolved mouse brain proteome. *Nat Neurosci* 18:1819–1831.
- Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M (2006) In-gel digestion for mass spectrometric characterization of proteins and proteomes. *Nat Protoc* 1:2856–2860.
- Spellman DS, Wildsmith KR, Honigberg LA, Tuefferd M, Baker D, Raghavan N, Nairn AC, Croteau P, Schirm M, Allard R, Lamontagne J, Chelsky D, Hoffmann S, Potter WZ (2015) Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's disease neuroimaging initiative (ADNI) CSF. *Proteomics Clin Appl* 9:715–731.
- Surugiu R, Catalin B, Dumbrava D, Gresita A, Olaru DG, Hermann DM, Popa-Wagner A (2019) Intracortical administration of the complement C3 receptor antagonist trifluoroacetate modulates microglia reaction after brain injury. *Neural Plast* 2019:1071036.
- Tabula Muris Consortium (2018) Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. *Nature* 562:367–372.
- van Steenoven I, Noli B, Cocco C, Ferri GL, Oeckl P, Otto M, Koel-Simmeling MJA, Bridel C, van der Flier WM, Lemstra AW, Teunissen CE (2019) VGF peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. *Int J Mol Sci* 20:E4674.
- Wendt S, Maricos M, Vana N, Meyer N, Guneykaya D, Semtner M, Kettenmann H (2017) Changes in phagocytosis and potassium channel activity in microglia of 5xFAD mice indicate alterations in purinergic signaling in a mouse model of Alzheimer's disease. *Neurobiol Aging* 58:41–53.
- Wiggins HL, Rappoport JZ (2010) An agarose spot assay for chemotactic invasion. *Biotechniques* 48:121–124.
- Wolf SA, Boddeke HW, Kettenmann H (2017) Microglia in physiology and disease. *Annu Rev Physiol* 79:619–643.
- Xu Y, Hu W, Liu Y, Xu P, Li Z, Wu R, Shi X, Tang Y (2016) P2Y6 receptor-mediated microglial phagocytosis in radiation-induced brain injury. *Mol Neurobiol* 53:3552–3564.
- Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keefe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, Liddelow SA, Zhang C, Daneman R, Maniatis T, Barres BA, Wu JQ (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J Neurosci* 34:11929–11947.
- Zhao X, Liao Y, Morgan S, Mathur R, Feustel P, Mazurkiewicz J, Qian J, Chang J, Mathern GW, Adamo MA, Ritaccio AL, Gruenthal M, Zhu X, Huang Y (2018) Noninflammatory changes of microglia are sufficient to cause epilepsy. *Cell Rep* 22:2080–2093.